Evidence map›Paper›PMID 31450841›Full record

ReviewMedicina (Kaunas, Lithuania)2019

Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies.

Ali Alqahtani, Zubair Khan, Abdurahman Alloghbi, Tamer S Said Ahmed, Mushtaq Ashraf, Danae M Hammouda

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 2 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 2 syntheses or guidelines pooled it, 258 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ali AlqahtaniDepartment of Internal Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43614, USA. Ali.Alqahtani3@utoledo.edu.
Zubair KhanDivision of Gastroenterology and Hepatology, Health Science Center at Houston, The University of Texas, Houston, TX 77030, USA.
Abdurahman AlloghbiDepartment of Internal Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43614, USA.
Tamer S Said AhmedDepartment of Internal Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43614, USA.
Mushtaq AshrafDivision of Hematology and Medical Oncology, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43614, USA.
Danae M HammoudaDivision of Hematology and Medical Oncology, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43614, USA.
University of Toledo · USThe University of Texas Health Science Center at Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors worldwide. HCC is a complex process that is associated with several etiological factors, which in turn result in aberrant activation of different cellular and molecular pathways and the disruption of balance between activation and inactivation of protooncogenes and tumor suppressor genes, respectively. Since HCC most often occurs in the setting of a diseased or cirrhotic liver and most of the patients are diagnosed at the late stage of disease, prognosis is generally poor. At present, limited treatment options with marginal clinical benefits are available. Systemic therapy, particularly in the form of conventional cytotoxic drugs, are generally ineffective. In recent years, molecular-targeted therapies have been clinically used to treat various cancers, including liver cancer. This approach inhibits the growth of tumor cells by interfering with molecules that are involved in carcinogenesis, which makes it more selective and specific than cytotoxic chemotherapy. Many clinical trials have been carried out while using molecular targeted drugs in advanced HCC with many more in progress. The clinical trials in HCC to date have evaluated a single-targeted therapy alone, or two or more targeted therapies in parallel. The aim of this review is to provide insight of various molecular mechanisms, leading to HCC development and progression, and also the range of experimental therapeutics for patients with advanced HCC. The review will summarize different clinical trials data the successes and failures of these treatments, as well as the most effective and approved drugs designed against HCC.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularHumansIncidenceInterleukin-6Liver NeoplasmsNF-kappa BRisk FactorsSignal TransductionTransforming Growth Factor alphaTumor Necrosis Factor-alphaAntineoplastic AgentsIL6 protein, humanInterleukin-6NF-kappa BTransforming Growth Factor alphaTumor Necrosis Factor-alphahepatocellular carcinomamolecular pathwaysprecision medicinetargeted therapy

Identifiers

PMID31450841
PMCPMC6780754
OpenAlexW2969744830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.